Uhh….I have always been VERY consistent. You take it as bashing RGRX…what I have done for a long time is bash FINKELSTEIN and what a #$%$ job he has done. I have been doing that for years now. So you are very wrong in hyping to yourself that I only started when RGRX was aroudn 5 cents. why don't you bash bocamp similarly? He too has often posted how horrible Finkelsten has been. But if bocamp bashes Finkel , it is okay? But if sno bashes Finkel, it isn't?
And donker, you're nuts. I don't cpome out with the short stuff every time RGRX is up. I have consistently, for years, posted the facts the the reported short interest does not match with what the SEC believes. I posted that when RGRX was both high and low.
Isn't that a hoot….or shall I say , LIE…FINRA reports there is short interest in RGRX.
On Monday, 49,000 shares were shorted. On Tuesady, 19,000 shares shorted. Today, there was 31,000 shares shorted. Three days, total shorted, 99,000 shares. The reason why there is no "reported" short interest is because MM's are exempt from telling the SEC.. Think about it….31,00 shorted today and the total volume was 71,000…that's about 45% of all volume shorted.
The fun news is??? The MM (likely NITE) just keeps on shorting. There isn't enough buy/sell/buy/sell/buy/sell to day trade and cover their shorts..…so it all get's added on to their ..which they do NOT report to the SEC. And BTW? MM's are exempt from reporting short to SEC and they are exempt from borrowing shares. So in essence, NITE is naked short. That doesn't mean they won't have to cover at some point. the question is???? NITE still firmly believes RGRX is a POS retail bankrupt spec penny bio. But if England pans out, they will feel some real pain and regret they they provided, short, all these shares at the 20 cent level. BUt we need England news to confirm.
I'll try to paste it. if not, go to Pubmed and search just "thymosin" (not b4)
"Thymosin beta4 (TB4) has multiple functions in cellular response in processes as diverse as embryonic organ development and the pathogeneses of disease, especially those associated with cardiac coronary vessels. However, the specific roles played by TB4 during heart valve development in vertebrates are largely unknown. Here, we identified a novel function of TB4 in endothelialmesenchymal transformation (EMT) in cardiac valve endocardial cushions in zebrafish. The expressions of thymosin family members in developing zebrafish embryos were determined by whole mount in situ hybridization. Of the thymosin family members only zTB4 was expressed in the developing heart region. Cardiac valve development at 48 h post fertilization was defected in zebrafish TB4 (zTB4) morpholino-injected embryos (morphants). In zTB4 morphants, abnormal linear heart tube development was observed. The expressions of bone morphogenetic protein (BMP) 4, notch1b, and hyaluronic acid synthase (HAS) 2 genes were also markedly reduced in atrio-ventricular canal (AVC). Endocardial cells in the AVC region were stained with anti-Zn5 antibody reactive against Dm-grasp (an EMT marker) to observe EMT in developing cardiac valves in zTB4 morphants. EMT marker expression in valve endothelial cells was confirmed after transfection with TB4 siRNA in the presence of transforming growth factor β (TGFβ) by RT-PCR and immunofluorescent assay. Zn5-positive endocardial AVC cells were not observed in zTB4 morphants, and knockdown of TB4 suppressed TGF-β-induced EMT in ovine valve endothelial cells. Taken together, our results demonstrate that TB4 plays a pivotal role in cardiac valve formation by increasing EMT.1.
hope someone knows somethong we don't! At least to the positive.
On Monday, 49,000 shares shorted. Yesterday, 20,00 share shorted. NITE is not happy. They've capped us for quite a while. Us on this board, some of which have nibbled, can't breach the low 20 cents where MM's cap us (volume wise)….it needs bigger volume. So the opening 43,000 is a nice indication. we need some mid six figure volume days of buying to rattle NITE's cages. They are sittting pretty well short here, by now. They just know in their hearts that RGRX is a POS.
Once and for all…get it..there is no dark pool trading in RGRX. No dark pool outfit would bother with it…they don't really do OTC BB stock….and they certainly don't "dark pool" a stock that trades, like today..4,000. That 4,00 shares has a value of $800.
Write it on a blackboard.…50 times.…"there is no dark pool conspiracy or manipulation.…in RGRX". Any shorting you see in RGRX is simply the market maker (largely NITE)..keeping a cap on RGRX, because they are already short quite a bit - as a position trade. MM's do not have to report their short positions, or borrow stock against their short. They are MM exempt from doing either. No one really knows what the shprt interest here is….but just add up the FINRA stats over last couple years…..and it is a lot.
Show me a time when RGRX trades 1 million shares a day, for a few weeks time….then you might legitimately think some of that volume ends up in an anonymous dark pool. Even on a 50,000 share day in RGRX, it's only worth a total value of $10,000…no darlk pool here. Move on.
Interesting short figures of today, FINRA….53,000 traded, but 29,600 of that was traded short. Seeing as there was no active buy/sell/buy sell….it's common sense that the MM….I assume NITE.is very willing to short , or "cap" us at the 21 cent level. Anyone who has been here for a while has to see that the short interest "reported " the the SEC…is bogus. The SEC thinks there is about 6,00 shares short..or less. The various MM's….of which NITE is certainly the lead shorter….are my guesss…short close to SEVEN figures or more here. But since RGRX is thinly traded…they just declare their "capping" short position as normal day-to-day trading activity..which it is nothing of the sort. NITE is using the MM exemption of not having to BORROWE shares…or reporting to the SEC what they are really short…beccause of what they claim a ""MM exemption".
I don't think the NITE person trading RGRX reads this board. But if the Block Scoping report #34 comes back soon from the England NHS…to the England NICE…that they support a final "appraisal" by NICE of TB 4 dry eye….it's a sound bet that a handful of months after, that NICE will also approve. Because it was NICE who sent it to NHS in the first place, wishing it. Everyone on this board will know…and probably buy stock , on that NICE gamble- if NHS says "go".. Because the NHS says "okay"……What will NITE do then? we all will buy whatever they short to us.until they say 'uncle"???…and they are short low 7 figures shares already (my guess)???
RGRX may ask to go direct to a Phase 3, but will the FDA allow it? Under that compassionate use IND, RGRX dosed FOUR patients, all responded. Qustion is, will the pencil geeks at the FDA allow RGRX to transverse INTO a phase 3, based on not even a real phase 2…only a 4 patient physician test..not really trial.
Second, the FDA would want a decent no# of pts in phase 3. where will money come from. It is possible that RGRX applies for an Orphan Grant. Deadline was earyl feb to ask. Decision around October, money given November.
RGRX is trying a "hail mary" pass with EB and FDA. It took 7 years to do the trial, and they could only get 30 patients. So it is unlikely an EB trial will be repeated. Sounds like RGRX might try something, but I don't know if the FDA will listen. There is no drug for EB. But the trial results show that a placebo water gel did almost as good, showing some efficacy, as TB 4. But how can that be, the FDA will ask. If a placebo water gel showed efficacy, why isn't every EB pt now on a water gel? RGRX needs to explain the placebo response. How did it happen. Did TB 4 have efficacy? Did RGRX mix up the placebo with TB 4? The FDA is very trial sticky….and data sticky. Even with a consultant, the data shown, is that TB 4 did not match water gel placebo.. RGRX has some explaining to do.
Yes, I had same problem….I can't find link to Block 34. We're next up there. I recall t was only like 6 drugs…not 10 or 12 to review……..and they seemed straight forward ones.not complicated, controversial or a budget killer. Like Gilead wants like $86,000 for it's new HCV pill.
I think we'll see it in a few weeks. But then we have to wait. Because NICE just needs the NHS blessing for their final appraisal. But I read that if the NHS gives it's blessing..the vast majority of drugs will then get's NICE's final approval too. So even though.if the NHS comes back in Block 34 and says "yes"……it will still be a while…..but if NHS says "yes"…the handwriting is on the wall. And approval is pretty likely then by NICE.
if NHS says "yes" in block 34..my hunch is you will see a good sized pop in RGRX share price. And it will confuse the heck out of NITE..because RGRX is NOT doing any press on the NICE. Only this board knows..and we know if the NHS says "yes"…..it's odds on that it will get final approval from NICE.
God…would NITE be #$%$ off to get blindsided….no news they see… why RGRX rises (after NHS, yes?)
I think it all depends on WHAT drugs are included in the BLOCK 34 Scope. I lost that link……It depends on how many are in block 34, and how complicated the diseases. or also, is the drug being looked at controversial? Is it horribly high priced? Are there side effects that concern the NHS?
I think the review for TB 4 could go pretty quickly. TB 4 won't be horribly expensive (like a $70,000 HCV drug or a similar one for MS)…there are no side effect risks..there is a large number of pts wishing something in the UK for dry eye..and the NHS has basic trial data.. If the other drugs being looked at in Block 34 are as simple…..and there aren't many being reviewed…it could come quickly. Can you find what and how many in #34?
My biggest mistake was not seeing that the "best gamble" was on TB 4…..but the man standing in front of that gamble is JJ Finkelstein. That was my biggest mistake…thinking that he was capable of guiding TB 4 and running RGRX….. 25 years later and $195,000,000.00 #$%$ away by Finkelstein….what's changed? NOT MUCH! He's doing what he does best….he just awarded himself ANOTHER 500,000 options..dilution be damned…and his latest equity financing for RGRX was at the lowest ever…12 cents…..and to get that, diluted the compay by 20%. There's not so many more times you can do that.
So stick to truth dopey donk…and the truth is that the two Steins could have cared less about the single most important meeting to ever have been had on TB 4…in 25 years…that was critical scoping meeting on Jan 9, 2014 by NICE. NICE wishes companies to attend and explain their drug..and give whatever info and input they like. Did ANYONE from RGRX go????? NO. It is a direct flight from DC to London…5-6 hours.
But show Finkelstein or Goldstein that there is a total BOONDOGGLE Kumbaya Conference on Thymosins.…in Sicily or Italy…..and they are there in a FLASH….probably for a full two weeks…with ther wives in tow….. All expenses paid…….by us. Who needs England, or NICE.…or a TB 4 approval.…when you have Italy and Sicily to go to…the shopping……the food…the wine….the views….
You want the, dope… donkey??? Then try toi explain this, buddy boy. For a bunch of years, RGRX has set up thru GWU this "Kumbaya Thymosin Conference"……all the thymosin reasearch is funded by others and others pay for the trips.. I showed you about 3,500 abstracts and research projects done on Thymosins. What good came of it? NONE. Except free trips to conferences in Sicily or Italy……and Thymosin abstracts get "published"….but no one, no pharma, no investment place..could give a damn. SO ANSWER THIS DONKER:
How is it that Finkelstein & Goldstein drop everything..to fly to a free luxury vacation/conference in Italy and previously to Sicily…..all free & paid..for the same set of same old washed up Thymosin researchers….who've done maybe 3,500 worthless abstracts on thymosin..paid by someone else..and no one cares. HOWEVER…..the single most important thing that could TRANSFORM RGRX and TB 4…is the possible upcoming approval review in ENGLAND by the NICE and NHS there. I showed here exact quotes -- that NICE encourages the owning company to come and present all they have at the scoping meeting - from which the NHS decides if they agree to allow the process to go ahead. NO ONE FROM RGRX thought an was worth their while to attend. BUT A BOONDOGGLE of worthless thymosin conferences in Sicily and Italy ARE WORTH EVERY PENNY?
Finkelstein…Goldstein….ALL the "STEINS" should be dumped. Since the mid 1980's they have spent over $195,000,000.00.and of that THEY collected LARGE amount in salary, bonus, raises, expenses, 401-k, pension, all kinds of insurance..and whatever travel and entertainment they wish. All paid by us. BUT WHEN TB 4 come to NICE for a final scoping meeting………Finkelstein..Goldstein..the …..blow it off? The single most important meeting for RGRX? And they blow it off? But they rush to a FREE "Kumbaya Conference" in Sicily and Italy. . Finkelstein reads this board. Tell him he sucks, big time.
I checked PubMed for the actual published abstracts. Pretty pitiful.
For Thymosin Beta 4 there are 637 abstracts of research done.
For just 'Thymosin" there are 2,609 abstracts of research done.
What outcomes have been achieved from 3,246 Thymosin abstracts????
RGRX has been at it since the mid 1980's. Joe McNay has been on the RGRX Board since 1987……..RGRX has SPENT about $195,000,000.00……and has almost nothing to show for it. Much of that $195 million went to salaries, benefits, bonuses, etc… and overhead…they haven't really done that many trials. But a lot went into lawyers and patent work too……but the facts stand……637 TB 4 abstracts I see…2,609 Thymosin abstracts…..RGRX has spent $195 million of shareholder money since the late 1980's……..and nothing much has happened and very little has worked as they wanted.
You just have to take the hype of this Thymosin Conference with a grain of salt. No other pharmas care attend. It is the annual "Fink & Goldie Campfire Kumbaya".
I'm sure the RGRX folks will bring the wives to Italy and extend their trip while they are there. Who wouldn't?
total boondoggle..a paid vacation for the same people and same names/researchers to have their 'kumbaya-around-the-campfire" on how wonderful & smart they are to study Thymosins (but someone else is always paying for their research or trip here). But nothing ever comes of it…their reserach is ignored by all big pharmas…no one wants to partner TB 4…their TB 4 abstracts may get printed somewhere, but no one cares..I finally gave up counting how many TB 4 published abstracts I could find….well over 400. what good did it do? nothing.
OB stock should be trading higher than where it is….their junk is almost gone now… all Specialty..and freeing up maybe $100 million reserves too. But I think what actually HURTS the share price is that WTM usues OB as their personal piggy bank. OB pays out $80 million in dividends…about 70% of that all goes to WTM. OB is paying out the majority or earnings out, in dividends. I would rather see OB cut the dividend by at least 50%..then take that money and build, expand or buy more specialty insurance areas. Buy a small company, or hire more top notch sales guys. Invest in the company..grow revenues faster…and the stock price will follow. If OB keeps doing what they are doing….paying out majority of net earnings soley to WTM….they won't grow as fast as they could, and the market will discount your share price on that.
OB could be a lot more, if they didn't #$%$ away so much money giving back to WTM in dividends. I wouldn't mind if the ELIMINATED the dividend. Imagine what OB coudl do with the freed up $80 million yearly..buy companies, expand offerings..hire the best people….grow revenues fast - and your stock price will go way up. warren Buffet never paid a dividend, and look what HE did with the kept money over time.. OB should keep it and grow it, too.
Have a look at MNKD today. was a $4 stock, but up 100% on an FDA Advisory Committee that said they would recommend approving. Now it goes to the FDA for final decision. MNKD is up 100%…..43% of the float in MNKD is short….63 million shares short.
MAy we hope and pray that NITE was shorting that one :)
RGRX could move far more (percent wise)…because MNKD was at $4 coming into the approval review….the shares were high because of the possibility. RGRX shares are priced by NITE for eventual bankruptcy….20 cents….but an approval in England.thru NICE.would blindside the market.…because RGRX is priced for going out of business….and certainly not coming into a possible NICE marketing approval. Apparently, Finkelstein and others there could have cared less. Someone should have attended the important January 9, 2014 scoping meeting….to ensure it all goes as good as possible for NICE - to understand TB 4.
yahoo again cut of post..
from NICE: "At the scoping workshop, NICE encourages the manufacturer or sponsor provide preliminary detailsof the evidence it woudl submit if NICE were asked 9by the NHS) to appraise teh technology."
Dr. Sosne or Dr. Goldstein should have been there. You get one shot with this…we are there with only a 75 patient phs 2 trial data….it needs explaining to help along….and I think the only reason this supposed company in Korea is in board with a couple million $.…is what they know from the inside of the Korean gov;'t …and their connection to NICE International and possible approval. Once again..mgmt screws up. How do they reward themselves? Another 1.4 million options for free. Courtesy of us.
It's an option. I didn't check the dates, but I assume at least a 5 year option. They get to buy stock at 21 cents.. That 21 cents a share they buy/pay (possibly)…does go to the company….but the potential few hundred thousand $$ isn't worth the 1,400,000 share dilution.
I guess they deserve some options, but not what they got. That is par for the course with them. The only thing on the horizon that could make RGRX go up (perhaps a lot) is the outcome at NICE and possible TB 4 approval in England for dry eye. But not only is RGRX hiding & not disclosing that possibilty to investors, it is worse that they seem… that they couldn't have cared less about it….even though a TB 4 approval in a Major country is TRANSFORMATIONAL to RGRX and TB 4. A marketing approval in England would remove a lot of financial worry and INCREASE the liklihood of a REAL big pharma partner coming in.The NICE states this:
The odds that someone from ORA went are slim to none. RGRX has no meney to pay them. dr. Sosne shoudl have gobne, or Goldstein.they can explain hpo wthey think TB 4 works. Sosne did TWO human trials outside the ORA Inc one…one in severe dry eye and one in eye NK.where we just got FDA Orphan Status.
It was just plain DUMB not to send someone…..a ONE SHOT deal to present what you want and explain any and all qiuestions of TB 4 dry eye. LOOK AT IT THIS WAY! what if you are on the NICE reviewing team, doing the scoping workshop….and the company RGRX cares so little about the opportunity or NICE…, that they send NO ONE TO ATTEND. if I was a person on the NICE team..I might consider the RGRX people not very worthy. If mgmt could give a damn about attending an IMPORTANT scoping meeting - to be the possible FIRST WORLDWIDE DRUG APPROVAL for TB 4….then why should the NICE team consider TB 4 any good…if management could care less by not attending.